Wills C Dunham1, Matthew B Weinger2, Jason Slagle2, Mias Pretorius3, Ashish S Shah4, Tarek S Absi4, Matthew S Shotwell5, Marc Beller6, Erica Thomas7, Cindy L Vnencak-Jones8, Robert E Freundlich1, Jonathan P Wanderer9, Warren S Sandberg9, Miklos D Kertai10. 1. Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN, USA. 2. Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN, USA; Center for Research and Innovation in System Safety, Vanderbilt University Medical Center, Nashville, TN, USA. 3. Department of anesthesiology, Vanderbilt University Medical Center, Nashville, TN, USA. 4. Department of Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN, USA. 5. Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA. 6. Center for Precision Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. 7. Department of Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, TN, USA. 8. Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA. 9. Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA. 10. Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: miklos.kertai@vumc.org.
Abstract
OBJECTIVES: The Preemptive Pharmacogenetic-guided Metoprolol Management for Atrial Fibrillation in Cardiac Surgery (PREEMPTIVE) pilot trial aims to use existing institutional resources to develop a process for integrating CYP2D6 pharmacogenetic test results into the patient electronic health record, to develop an evidence-based clinical decision support tool to facilitate CYP2D6 genotype-guided metoprolol administration in the cardiac surgery setting, and to determine the impact of implementing this CYP2D6 genotype-guided integrated approach on the incidence of postoperative atrial fibrillation (AF), provider, and cost outcomes. DESIGN: One-arm Bayesian adaptive design clinical trial. SETTING: Single center, university hospital. PARTICIPANTS: The authors will screen (including CYP2D6 genotype) up to 600 (264 ± 144 expected under the adaptive design) cardiac surgery patients, and enroll up to 200 (88 ± 48 expected) poor, intermediate, and ultrarapid CYP2D6 metabolizers over a period of 2 years at a tertiary academic center. INTERVENTIONS: All consented and enrolled patients will receive the intervention of CYP2D6 genotype-guided metoprolol management based on CYP2D6 phenotype classified as a poor, intermediate, extensive (normal), or ultrarapid metabolizer. MEASUREMENTS AND MAIN RESULTS: The primary outcome will be the incidence of postoperative AF. Secondary outcomes relating to rates of CYP2D6 genotype-guided prescription changes, costs, lengths of stay, and implementation metrics also will be investigated. CONCLUSIONS: The PREEMPTIVE pilot study is the first perioperative pilot trial to provide essential information for the design of a future, large-scale trial comparing CYP2D6 genotype-guided metoprolol management with a nontailored strategy in terms of managing AF. In addition, secondary outcomes regarding implementation, clinical benefit, safety, and cost-effectiveness in patients undergoing cardiac surgery will be examined.
OBJECTIVES: The Preemptive Pharmacogenetic-guided Metoprolol Management for Atrial Fibrillation in Cardiac Surgery (PREEMPTIVE) pilot trial aims to use existing institutional resources to develop a process for integrating CYP2D6 pharmacogenetic test results into the patient electronic health record, to develop an evidence-based clinical decision support tool to facilitate CYP2D6 genotype-guided metoprolol administration in the cardiac surgery setting, and to determine the impact of implementing this CYP2D6 genotype-guided integrated approach on the incidence of postoperative atrial fibrillation (AF), provider, and cost outcomes. DESIGN: One-arm Bayesian adaptive design clinical trial. SETTING: Single center, university hospital. PARTICIPANTS: The authors will screen (including CYP2D6 genotype) up to 600 (264 ± 144 expected under the adaptive design) cardiac surgery patients, and enroll up to 200 (88 ± 48 expected) poor, intermediate, and ultrarapid CYP2D6 metabolizers over a period of 2 years at a tertiary academic center. INTERVENTIONS: All consented and enrolled patients will receive the intervention of CYP2D6 genotype-guided metoprolol management based on CYP2D6 phenotype classified as a poor, intermediate, extensive (normal), or ultrarapid metabolizer. MEASUREMENTS AND MAIN RESULTS: The primary outcome will be the incidence of postoperative AF. Secondary outcomes relating to rates of CYP2D6 genotype-guided prescription changes, costs, lengths of stay, and implementation metrics also will be investigated. CONCLUSIONS: The PREEMPTIVE pilot study is the first perioperative pilot trial to provide essential information for the design of a future, large-scale trial comparing CYP2D6 genotype-guided metoprolol management with a nontailored strategy in terms of managing AF. In addition, secondary outcomes regarding implementation, clinical benefit, safety, and cost-effectiveness in patients undergoing cardiac surgery will be examined.
Authors: Valentin Fuster; Lars E Rydén; Davis S Cannom; Harry J Crijns; Anne B Curtis; Kenneth A Ellenbogen; Jonathan L Halperin; G Neal Kay; Jean-Yves Le Huezey; James E Lowe; S Bertil Olsson; Eric N Prystowsky; Juan Luis Tamargo; L Samuel Wann; Sidney C Smith; Silvia G Priori; N A Mark Estes; Michael D Ezekowitz; Warren M Jackman; Craig T January; James E Lowe; Richard L Page; David J Slotwiner; William G Stevenson; Cynthia M Tracy; Alice K Jacobs; Jeffrey L Anderson; Nancy Albert; Christopher E Buller; Mark A Creager; Steven M Ettinger; Robert A Guyton; Jonathan L Halperin; Judith S Hochman; Frederick G Kushner; Erik Magnus Ohman; William G Stevenson; Lynn G Tarkington; Clyde W Yancy Journal: Circulation Date: 2011-03-07 Impact factor: 29.690
Authors: J J Swen; M Nijenhuis; A de Boer; L Grandia; A H Maitland-van der Zee; H Mulder; G A P J M Rongen; R H N van Schaik; T Schalekamp; D J Touw; J van der Weide; B Wilffert; V H M Deneer; H-J Guchelaar Journal: Clin Pharmacol Ther Date: 2011-03-16 Impact factor: 6.875
Authors: Joseph P Mathew; Manuel L Fontes; Iulia C Tudor; James Ramsay; Peter Duke; C David Mazer; Paul G Barash; Ping H Hsu; Dennis T Mangano Journal: JAMA Date: 2004-04-14 Impact factor: 56.272
Authors: Thomas Rau; Roland Heide; Klaus Bergmann; Henrike Wuttke; Ulrike Werner; Nico Feifel; Thomas Eschenhagen Journal: Pharmacogenetics Date: 2002-08
Authors: I S Hamadeh; T Y Langaee; R Dwivedi; S Garcia; B M Burkley; T C Skaar; A B Chapman; J G Gums; S T Turner; Y Gong; R M Cooper-DeHoff; J A Johnson Journal: Clin Pharmacol Ther Date: 2014-03-17 Impact factor: 6.875
Authors: Paul Y Takahashi; Euijung Ryu; Jyotishman Pathak; Gregory D Jenkins; Anthony Batzler; Matthew A Hathcock; John Logan Black; Janet E Olson; James R Cerhan; Suzette J Bielinski Journal: Pharmgenomics Pers Med Date: 2017-02-14
Authors: Andrea Gaedigk; Katrin Sangkuhl; Michelle Whirl-Carrillo; Teri Klein; J Steven Leeder Journal: Genet Med Date: 2016-07-07 Impact factor: 8.822
Authors: Miklos D Kertai; Jonathan D Mosley; Jing He; Abinaya Ramakrishnan; Mark J Abdelmalak; Yurim Hong; M Benjamin Shoemaker; Dan M Roden; Lisa Bastarache Journal: Circ Genom Precis Med Date: 2021-03-01